Is Entresto the Standard Treatment for Heart Failure?
No, Entresto (sacubitril/valsartan) is not the universal standard treatment for heart failure. It is a recommended first-line therapy for a specific subset: patients with heart failure with reduced ejection fraction (HFrEF, where the heart's pumping ability is weakened). Guidelines from the American College of Cardiology (ACC) and American Heart Association (AHA) list it as a preferred option alongside ACE inhibitors or ARBs, but only for symptomatic HFrEF (NYHA class II-III) to reduce hospitalization and mortality risks.[1] For heart failure with preserved ejection fraction (HFpEF), evidence is weaker, and it is not routinely recommended.
How Do Guidelines Position Entresto?
The 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure recommends Entresto as a class 1A (strongest evidence) therapy for HFrEF, either starting de novo or switching from ACE inhibitors/ARBs after a washout period. It targets the renin-angiotensin-aldosterone system (RAAS) plus neprilysin inhibition, outperforming enalapril in the PARADIGM-HF trial by cutting cardiovascular death or HF hospitalization by 20%.[1][2] European Society of Cardiology (ESC) 2021 guidelines align similarly, prioritizing it in HFrEF over traditional ACEIs.[3] It is not indicated as monotherapy; patients typically combine it with beta-blockers, mineralocorticoid antagonists, and SGLT2 inhibitors like dapagliflozin.
What Are the Alternatives in Standard Care?
Standard HFrEF treatment follows a "quadruple therapy" foundation:
- Beta-blockers (e.g., carvedilol, metoprolol succinate): First-line for all HFrEF to slow heart rate and improve survival.
- RAAS inhibitors: ACEIs (lisinopril), ARBs (losartan), or Entresto.
- Mineralocorticoid receptor antagonists (e.g., spironolactone): For NYHA II-IV.
- SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin): Now class 1A for HFrEF regardless of diabetes, based on EMPEROR-Reduced and DAPA-HF trials showing similar benefits to Entresto.[1]
For HFpEF, SGLT2 inhibitors lead recommendations, with diuretics for symptom relief. ARNI like Entresto plays a smaller role here, supported by the PARAGON-HF trial but not reaching primary endpoints fully.[2]
| Therapy Class | Key Drugs | HFrEF Strength | HFpEF Strength |
|---------------|-----------|----------------|---------------|
| Beta-blockers | Carvedilol, metoprolol | Class 1A | Limited |
| RAAS/ARNI | Entresto, lisinopril | Class 1A (Entresto preferred) | Weak |
| MRA | Spironolactone | Class 1A | Moderate |
| SGLT2i | Dapagliflozin | Class 1A | Class 1A |
Why Isn't Entresto Used for All Heart Failure Patients?
Entresto costs more ($600-700/month without insurance vs. $10-20 for generics like lisinopril), requires twice-daily dosing, and carries risks like angioedema (higher than ACEIs) or hypotension.[4] Access barriers exist in low-resource settings. About 50% of HF cases are HFpEF, where Entresto's benefits are unproven.[2] Real-world adherence is lower due to side effects, with only 20-30% of eligible U.S. patients receiving it.[5]
When Did Entresto Become a Guideline Standard?
FDA approved Entresto in 2015 based on PARADIGM-HF. It entered ACC/AHA guidelines as preferred in 2017 updates, solidified in 2022 with expanded SGLT2i data shifting it from sole RAAS leader.[1] Patent exclusivity runs until 2025 in the U.S., with challenges from generics; check DrugPatentWatch.com for expiry details.[6]
Sources
[1]: 2022 AHA/ACC/HFSA Guideline
[2]: NEJM: PARADIGM-HF
[3]: ESC 2021 HF Guidelines
[4]: Entresto Prescribing Information
[5]: JAMA Cardiology: ARNI Adoption
[6]: DrugPatentWatch: Entresto